Company: Samsung Biologics Company Limited

Bloomberg ticker: 207940 KS

Market cap: US$3,051m

Background: Samsung Biologics Company Limited is a contract manufacturer and developer of biopharmaceutical products–drugs made from biological sources. The company currently has four production plants, with a fifth scheduled to open in 2025. Clients include leading global companies likePfizer, GlaxoSmithKline, Eli Lilly, and AstraZeneca.

World Class Benchmarking of Samsung Biologics

(Click on image to enlarge)

• Profitable Growth rank of 4 was up compared to the prior period’s 5th rank
• This is above average performance compared to 360 large Health Care companies worldwide
• Profitability rank of 4 was the same as its Growth rank of 4
• Profitability rank of 4 was up compared to the prior period’s 5th rank
• This is above average performance compared to peers
• Growth rank of 4 was up compared to the prior period’s 5th rank
• This is above average performance compared to peers

More By This Author:

Asian Stock: ENN Natural Gas
Asian Stock - MIXI
Asian Stock: Thai Union Group